Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects have primary diagnosis of ADHD~* Females of childbearing potential must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test~* Subject has an IQ score of \>_ 80~* Subject is able to complete as least the Basic Test of the PERMP assessment~Exclusion Criteria:~* Subject has a comorbid psychiatric diagnosis such as Axis II disorders or severe Axis I disorders~* Subject is taking Strattera(r)~* Subject has a recent history of suspected substance abuse or dependence disorder

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: ACTIVE_COMPARATOR): The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
- Placebo (Type: PLACEBO_COMPARATOR): The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
- Concerta (Type: ACTIVE_COMPARATOR): CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily

Based on this trial design, predict the completion outcome and termination type (if applicable).